Concepedia

J. M. Fehling

JM

Statistics

Publications

2

Citations

29

H-Index

2

Active since

2008

J. M. Fehling is an author specializing in pharmacodynamics of anticancer agents, cancer pharmacology, and pharmacodynamics of anticancer drugs.

Publications per year

2008–2008

2

Publications

2

A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors

Lee S. Rosen, Peter S. Galatin, J. M. Fehling et al. · Journal of Clinical Oncology · 2008 · 17 citations

, , +14

A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)

Heather A. Wakelee, J. M. Fehling, Julian R. Molina et al. · Journal of Clinical Oncology · 2008 · 12 citations

, , +17

1–2 of 2